Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.67 |
| ▸ | MAPT | P10636 | 5/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.67 |
| ▸ | HPGD | P15428 | 3/20 | 0.67 |
| ▸ | GAA | P10253 | 2/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.54 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.54 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.50 |
| ▸ | GPR3 | P46089 | 1/20 | 0.48 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | NQO2 | P16083 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.46 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30939014 | 1.00 | ALDH1A1 (0.67) | ALDH1A1MAPTKDM4EHSD17B10HPGD | |
| SCHEMBL29364974 | 0.81 | MAPT (0.62) | ALDH1A1MAPTKDM4EHSD17B10HPGD | |
| SCHEMBL503252 | 0.81 | MAPT (1.00) | ALDH1A1MAPTKDM4EHSD17B10HPGD | |
| SCHEMBL103601 | 0.81 | MAPT (0.62) | ALDH1A1MAPTKDM4EHSD17B10HPGD | |
| SCHEMBL29444102 | 0.81 | MAPT (1.00) | ALDH1A1MAPTKDM4EHSD17B10HPGD | |
| Ammonia Solution, Strong SCHEMBL27821564 | 0.78 | MAPT (0.59) | ALDH1A1MAPTKDM4EHSD17B10HPGD | |
| SCHEMBL11011451 | 0.78 | MAPT (0.59) | ALDH1A1MAPTKDM4EHSD17B10HPGD | |
| Water SCHEMBL27864881 | 0.78 | MAPT (0.59) | ALDH1A1MAPTKDM4EHSD17B10HPGD | |
| SCHEMBL18873137 | 0.78 | NQO2 (0.57) | ALDH1A1MAPTKDM4ECYP1A2MEN1 | |
| Hydrochloric Acid SCHEMBL28590789 | 0.76 | MAPT (0.56) | ALDH1A1MAPTKDM4EHSD17B10HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322803-A1 | SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | BRISTOL MYERS SQUIBB CO (US) | 2023-10-12 | — | — | US | disclosed |
| WO-2023023867-A1 | COMPOUNDS FOR REDUCING CHOLESTEROL AND TREATING LIVER AND KIDNEY DISEASE | MCMASTER UNIVERSITY (CA) | 2023-03-02 | — | — | WO | disclosed |
| CN-110603253-B | Heteroaryl phenylamino quinolines and analogs | 拜耳公司 | 2023-01-20 | — | — | CN | disclosed |
| US-11457629-B2 | Heteroarylphenylaminoquinolines and analogues | BAYER AKTIENGESELLSCHAFT (DE) | 2022-10-04 | — | — | US | disclosed |
| EP-3615523-B1 | HETEROARYLPHENYLAMINOQUINOLINES AND ANALOGUES | BAYER AG (DE) | 2021-07-14 | — | — | EP | disclosed |
| EP-3442047-B1 | ORGANIC LIGHT-EMITTING DISPLAY APPARATUS | SAMSUNG DISPLAY CO LTD (KR) | 2021-05-05 | — | — | EP | disclosed |
| US-20200196602-A1 | HETEROARYLPHENYLAMINOQUINOLINES AND ANALOGUES | BAYER AKTIENGESELLSCHAFT (DE) | 2020-06-25 | — | — | US | disclosed |
| EP-3615523-A1 | HETEROARYLPHENYLAMINOQUINOLINES AND ANALOGUES | Bayer Aktiengesellschaft (DE) | 2020-03-04 | — | — | EP | disclosed |
| CN-110603253-A | Heteroaryl phenylamino quinolines and analogs | 拜耳公司 | 2019-12-20 | — | — | CN | disclosed |
| EP-3442047-A1 | ORGANIC LIGHT-EMITTING DISPLAY APPARATUS | Samsung Display Co., Ltd. (KR) | 2019-02-13 | — | — | EP | disclosed |
| US-20140309231-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2014-10-16 | — | — | US | disclosed |
| US-8846664-B2 | Pyrazinopyrazines and derivatives as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| EP-2282999-B1 | AMINO-QUINOXALINE AND AMINO-QUINOLINE COMPOUNDS FOR USE AS ADENOSINE A2A RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2014-05-21 | — | — | EP | disclosed |
| US-20140066406-A1 | Phosphorus Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2014-03-06 | — | — | US | disclosed |
| US-20130225528-A1 | Phosphorus Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225527-A1 | Phosphorus Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-7956056-B2 | Certain 1H-imidazo[4,5-B]pyrazin-2(3H)-ones and 1H-imidazo[4,5-B]pyrazin-2-ols, compositions thereof, and methods for their use | CYTOKINETICS, INC. (US) | 2011-06-07 | — | — | US | disclosed |
| US-20100093741-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. | 2010-04-15 | — | — | US | disclosed |
| WO-2008101979-A1 | QUINOXALINE COMPOUNDS AND USE THEREOF | MERCK SERONO S.A. (CH) | 2008-08-28 | — | — | WO | disclosed |
| US-20070093491-A1 | Novel condensed n-pyrazinyl-sulphonamides and their use in the treament of chemokine mediated diseases | ASTRAZENECA AB (SE) | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309231-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS | NPPA, NAT1, NPM1 | ALDH1A1 646/4885MAPT 2023/4885KDM4E 2934/4885 |
| US-20140066406-A1 | Phosphorus Derivatives as Kinase Inhibitors | PHKA1, PIK3CA, PHKA2 | ALDH1A1 4707/4885MAPT 3621/4885KDM4E 1527/4885 |
| US-20230322803-A1 | SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | DDX21, HRAS, RPL17 | ALDH1A1 1946/4885MAPT 3829/4885KDM4E 2305/4885 |
| US-20070093491-A1 | Novel condensed n-pyrazinyl-sulphonamides and their use in the treament of chemokine mediated diseases | CCL2, CCL11, CCR2 | ALDH1A1 2310/4885MAPT 2637/4885KDM4E 4607/4885 |
| US-20200196602-A1 | HETEROARYLPHENYLAMINOQUINOLINES AND ANALOGUES | PIK3C3, DDT, CYP4X1 | ALDH1A1 2092/4885MAPT 3159/4885KDM4E 648/4885 |
| US-20100093741-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | TNNC1, TNNI3, TNNT2 | ALDH1A1 4078/4885MAPT 300/4885KDM4E 4534/4885 |
| US-11457629-B2 | Heteroarylphenylaminoquinolines and analogues | PIK3C3, CYP4X1, CYP1A2 | ALDH1A1 1100/4885MAPT 3614/4885KDM4E 892/4885 |
| US-20130225527-A1 | Phosphorus Derivatives as Kinase Inhibitors | PHKA1, PIK3CA, PHKA2 | ALDH1A1 4707/4885MAPT 3621/4885KDM4E 1527/4885 |
| US-20130225528-A1 | Phosphorus Derivatives as Kinase Inhibitors | PHKA1, PIK3CA, PHKA2 | ALDH1A1 4707/4885MAPT 3621/4885KDM4E 1527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.